460044-25-1 Usage
Uses
Used in Pharmaceutical Industry:
3-Pyridinecarboxylic acid, 2-[(1,1-dimethylethyl)amino]-(9CI) is used as a therapeutic agent for the treatment of neurological and psychiatric conditions such as Parkinson's disease, erectile dysfunction, and addiction. It modulates dopamine receptor activity, particularly at the D2 and D4 receptors, providing symptomatic relief and improving the quality of life for patients.
Used in Oncology Research:
3-Pyridinecarboxylic acid, 2-[(1,1-dimethylethyl)amino]-(9CI) is used as a potential anti-cancer agent in preclinical studies. Its mechanism of action and potential therapeutic benefits in cancer treatment are currently being investigated, with the aim of developing novel cancer therapies and improving patient outcomes.
Check Digit Verification of cas no
The CAS Registry Mumber 460044-25-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,6,0,0,4 and 4 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 460044-25:
(8*4)+(7*6)+(6*0)+(5*0)+(4*4)+(3*4)+(2*2)+(1*5)=111
111 % 10 = 1
So 460044-25-1 is a valid CAS Registry Number.
460044-25-1Relevant articles and documents
Substituted 1,3-Dihydro-2H-pyrrolopyridin-2-ones as Potential Antiinflammatory Agents
Ting, Pauline C.,Kaminski, James J.,Sherlock, Margaret H.,Tom, Wing C.,Lee, Joe F.,et al.
, p. 2697 - 2706 (2007/10/02)
A series of analogues based on the 1,3-dihydro-2H-pyrrolopyridin-2-one ring system have been synthesized and shown to possess oral antiinflammatory activity in both the reverse passive Arthus reaction (RPAR) pleural cavity assay in rats and in the adjuvant-induced arthritic rat model (AAR).Several members of this series additionally exhibit an inhibitory effect on the in vivo production of prostaglandin- and leukotriene-derived products or arachidonic acid metabolism although these compounds exhibit no significant inhibitory activity against the cyclooxygenase and 5-lipoxygenase enzymes in vitro.Structure-activity relationships in this series are discussed.
